# LKFT catalysts: Lakefront Biotherapeutics NV PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/lkft/catalysts

> Lakefront Biotherapeutics NV (LKFT) has no upcoming catalysts in this calendar. The latest recorded is the GLPG3667 topline data readout, 1H 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for LKFT?

Lakefront Biotherapeutics NV (LKFT) has no upcoming catalysts in this calendar. The latest recorded is the GLPG3667 topline data readout, 1H 2026. Press release filed with the SEC (EX-99): "As announced in January 2025, Galapagos is seeking partners to take over its small molecule research portfolio and GLPG3667, its oral TYK2 inhibitor currently in Phase 3-enabling studies for systemic lupus erythematosus (SLE) and dermatomyositis (DM), with topline data expected in the first half of 2026." [Calendar and source filings](https://sec-api.dev/companies/lkft/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001171843-25-002429, https://www.sec.gov/Archives/edgar/data/1421876/000117184325002429/exh_991.htm (retrieved 2026-11-12). Last confirmed 2025-04-23. Cite: https://sec-api.dev/companies/lkft/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Lakefront Biotherapeutics NV |
| Ticker | LKFT (Nasdaq) |
| SEC CIK | 1421876 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/lkft |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2023 | [GLPG3667 trial start](https://sec-api.dev/pdufa/glpg3667) | LKFT |  | completed | "In April 2023, we announced that the first patient was dosed in GALARISSO, the Phase 2 study with GLPG3667 in DM patients." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1421876/000155837025003806/glpg-20241231x20f.htm)) |
| 1H 2025 | [GLPG5101 topline data readout](https://sec-api.dev/pdufa/glpg5101) | LKFT |  | scheduled | "Fully enrolled the indolent NHL (follicular lymphoma/marginal zone lymphoma) cohort, with new Phase 1/2 topline results expected to be presented at a medical conference in the first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1421876/000117184325002429/exh_991.htm)) |
| 2H 2025 | [GLPG5101 topline data readout](https://sec-api.dev/pdufa/glpg5101) | LKFT |  | scheduled | "Patient enrollment in the Mantle Cell Lymphoma (MCL) cohort is progressing, with updated Phase 1/2 topline results expected to be presented at a medical conference in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1421876/000117184325002429/exh_991.htm)) |
| October 8, 2025 | [Cadefrecitinib primary completion](https://sec-api.dev/pdufa/cadefrecitinib) | LKFT | Systemic Lupus Erythematosus | completed | "NCT05856448 (A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-08 (ACTUAL); Lead Sponsor Lakefront Biotherapeutics NV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05856448)) |
| October 13, 2025 | [Cadefrecitinib primary completion](https://sec-api.dev/pdufa/cadefrecitinib) | LKFT | Dermatomyositis | completed | "NCT05695950 (A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Lakefront Biotherapeutics NV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05695950)) |
| December 18, 2025 | [GLPG3667 topline data readout](https://sec-api.dev/pdufa/glpg3667) | LKFT | dermatomyositis | completed, met | "corticosteroid, OLE: open-label extension, QD: once daily, R: randomization On December 18, 2025, we announced topline results from the GALARISSO study, which are summarized below: The GALARISSO DM study met its primary endpoint, showing that" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1421876/000119312526130447/d54917dex993.htm)) |
| 2026 | [GLPG5301 topline data readout](https://sec-api.dev/pdufa/glpg5301) | LKFT |  | scheduled | "Patient enrollment in the Phase 1 part is progressing with topline results expected in 2026, which will guide Galapagos' development strategy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1421876/000117184325002429/exh_991.htm)) |
| 1H 2026 | [GLPG3667 topline data readout](https://sec-api.dev/pdufa/glpg3667) | LKFT |  | scheduled | "As announced in January 2025, Galapagos is seeking partners to take over its small molecule research portfolio and GLPG3667, its oral TYK2 inhibitor currently in Phase 3-enabling studies for systemic lupus erythematosus (SLE) and dermatomyositis (DM), with topline data expected in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1421876/000117184325002429/exh_991.htm)) |

## Drugs

- [Cadefrecitinib](https://sec-api.dev/pdufa/cadefrecitinib): Dermatomyositis, Systemic Lupus Erythematosus
- [GLPG3667](https://sec-api.dev/pdufa/glpg3667): dermatomyositis
- [GLPG5101](https://sec-api.dev/pdufa/glpg5101): 
- [GLPG5301](https://sec-api.dev/pdufa/glpg5301): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/lkft/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LKFT catalysts: Lakefront Biotherapeutics NV PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/lkft/catalysts

```bibtex
@misc{secapidev_companies_lkft_catalysts_20261116,
  title        = {LKFT catalysts: Lakefront Biotherapeutics NV PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/lkft/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_lkft_catalysts_20261116","title":"LKFT catalysts: Lakefront Biotherapeutics NV PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/lkft/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
